Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
SEER 
Seer Inc (SEER)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: SEER (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -37.98% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 99.24M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 272324 | Beta 1.59 | 52 Weeks Range 1.56 - 2.62 | Updated Date 04/2/2025 |
52 Weeks Range 1.56 - 2.62 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.39 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -587.2% |
Management Effectiveness
Return on Assets (TTM) -15.59% | Return on Equity (TTM) -23.91% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -109294798 | Price to Sales(TTM) 7 |
Enterprise Value -109294798 | Price to Sales(TTM) 7 | ||
Enterprise Value to Revenue 0.11 | Enterprise Value to EBITDA 1.72 | Shares Outstanding 55737100 | Shares Floating 41961608 |
Shares Outstanding 55737100 | Shares Floating 41961608 | ||
Percent Insiders 3.52 | Percent Institutions 66.9 |
Analyst Ratings
Rating 3.67 | Target Price 3 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Seer Inc
Company Overview
History and Background
Seer, Inc. was founded in 2017 with the aim of transforming proteomics by enabling unbiased, deep, and rapid proteomic analysis at scale. The company has focused on developing its proprietary Proteograph Product Suite to address challenges in proteomics research.
Core Business Areas
- Proteograph Product Suite: The core of Seer's business is its Proteograph Product Suite, which includes consumables, instruments, and software designed to enable comprehensive proteomic profiling. The suite aims to provide researchers with the tools necessary to gain deeper insights into proteins and their role in disease.
Leadership and Structure
Omead Ostadan serves as President and CEO. The company has a structured management team overseeing various aspects of operations, including research and development, manufacturing, and commercial activities.
Top Products and Market Share
Key Offerings
- Proteograph XT Assay Kit: Enables deep, unbiased proteomic profiling. While specific market share data is difficult to obtain due to the emerging nature of the proteomics market, Seer aims to capture a significant portion of research labs and biopharma looking for improved proteomic solutions. Competitors include companies offering mass spectrometry solutions and antibody-based protein detection methods, such as Thermo Fisher Scientific (TMO) and SomaLogic (not publicly traded).
- Proteograph Analysis Software: Proprietary software for data analysis generated by the Proteograph system. This is used in conjunction with the XT Assay kit for a streamlined proteomics workflow. Similar to the kit, market share is difficult to assess directly but faces competition from other bioinformatics solutions like those offered by QIAGEN (QGEN) or developed internally at large pharma companies.
Market Dynamics
Industry Overview
The proteomics market is experiencing rapid growth, driven by increasing demand for personalized medicine and drug discovery. Technological advancements are enabling deeper and more comprehensive proteomic analysis, expanding its applications.
Positioning
Seer aims to be a leader in unbiased proteomics with its Proteograph platform. Its competitive advantage lies in its ability to provide deeper proteomic insights compared to traditional methods, enabling researchers to identify novel biomarkers and drug targets.
Total Addressable Market (TAM)
The TAM for proteomics is estimated to be in the billions of dollars, potentially reaching over $20 billion by 2030. Seer is positioned to capture a portion of this market by offering a comprehensive solution for deep proteomic profiling.
Upturn SWOT Analysis
Strengths
- Proprietary Proteograph technology
- Potential for deep proteomic insights
- Strong management team
- Early mover advantage
Weaknesses
- Limited revenue generation to date
- Dependence on Proteograph adoption
- Requires significant capital investment
- High cost of goods
Opportunities
- Partnerships with biopharmaceutical companies
- Expansion into clinical diagnostics
- Development of new proteomic assays
- Increasing adoption of proteomics in research
Threats
- Competition from established players
- Technological advancements by competitors
- Regulatory hurdles
- Economic downturn impacting research budgets
Competitors and Market Share
Key Competitors
- TMO
- DHR
Competitive Landscape
Seer faces intense competition from established players with extensive resources and existing customer relationships. However, Seer's innovative technology provides a potential competitive edge if it can demonstrate superior performance and cost-effectiveness.
Major Acquisitions
Proteome Software, Inc.
- Year: 2024
- Acquisition Price (USD millions): 37.5
- Strategic Rationale: Enhance software capabilities for proteomic data analysis and to improve user experience within the Proteograph ecosystem.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by increasing adoption of the Proteograph platform and expansion of the customer base.
Future Projections: Future growth projections are dependent on increased sales of the Proteograph Product Suite and expansion into new market segments. Analyst estimates vary widely, reflecting the uncertainty inherent in early-stage growth companies.
Recent Initiatives: Recent initiatives include expanding the commercial team, developing new applications for the Proteograph platform, and forging strategic partnerships.
Summary
Seer is an early-stage growth company with promising technology in the proteomics space. Its success depends on increasing adoption of the Proteograph platform and expanding its market reach. While the company faces strong competition, its innovative approach and the potential for deep proteomic insights could drive long-term growth. Monitoring cash burn and securing strategic partnerships will be crucial for future success.
Similar Companies
- PACB
- ONTX
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Investor Relations
- Industry Reports
- Analyst Estimates
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated and may vary. Financial data is based on publicly available information and analyst estimates, which are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Seer Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2020-12-04 | Founder, CEO, & Chair of the Board of Directors Dr. Omid C. Farokhzad M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 134 | Website https://seer.bio |
Full time employees 134 | Website https://seer.bio | ||
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.